scholarly journals A new treatment strategy for severe refractory rheumatoid arthritis

2005 ◽  
Vol 1 (1) ◽  
pp. 8-8
Author(s):  
Rebecca Doherty
Keyword(s):  
Rheumatoid Arthritis ◽  
Treatment Strategy ◽  
Refractory Rheumatoid Arthritis ◽  
New Treatment

Ultrasound-triggered perfluorocarbon-derived nanobombs for targeted therapies of rheumatoid arthritis

2019 ◽  
Vol 7 (29) ◽  
pp. 4581-4591 ◽  
Author(s):  
Bihui Zhu ◽  
Liyun Wang ◽  
Jianbo Huang ◽  
Xi Xiang ◽  
Yuanjiao Tang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Targeted Therapies ◽  
Treatment Strategy ◽  
Theranostic Agent ◽  
New Treatment

The targeted US-triggered PFC-based “nanobombs” with US used to treat the RA in this work would offer a new treatment strategy and have a great potential for the application in the areas of theranostic agent and nanomedicine treatment.

scholarly journals Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report

2022 ◽  
Vol 8 ◽  
Author(s):  
Yutaka Kaneko ◽  
Takanori Murakami ◽  
Koichi Nishitsuka ◽  
Yuya Takakubo ◽  
Michiaki Takagi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Serous Retinal Detachment ◽  
Janus Kinase ◽  
Inflammatory Activity ◽  
Disease Modifying Antirheumatic Drugs ◽  
Vitreous Opacity ◽  
Refractory Rheumatoid Arthritis ◽  
Tnf Α ◽  
New Treatment ◽  
Systemic Arthritis

Baricitinib is a Janus kinase (JAK) inhibitor used to treat refractory rheumatoid arthritis and blocks the subtypes JAK1 and JAK2. A 35-year-old man with seronegative rheumatoid arthritis complicated by bilateral severe non-granulomatous panuveitis was resistant to steroid treatment, multiple conventional disease-modifying antirheumatic drugs (methotrexate and salazosulfapyridine), and TNF-α inhibitors (adalimumab and infliximab). Therefore, the TNF-α inhibitors were switched to baricitinib to decrease the activity of systemic arthritis. Along with the amelioration of inflammatory activity in seronegative rheumatoid arthritis, the inflammatory activity of uveitis was decreased. Vitreous opacity, serous retinal detachment, and anterior chamber cells showed improvement. Baricitinib was effective not only in refractory systemic arthritis but also in uveitis, which may provide a new treatment option for patients with refractory uveitis.

Fatal pneumocystis carinii pneumonia as a complication of methotrexate in rheumatoid arthritis

2003 ◽  
Vol 2 (1) ◽  
pp. 25-26
Author(s):  
M Suleman ◽  
◽  
MB Chaudri ◽  
C Deighton ◽  
RB Hubbard ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Female Patient ◽  
Pneumocystis Carinii Pneumonia ◽  
Low Dose ◽  
Opportunistic Infections ◽  
Pneumocystis Carinii ◽  
Dose Methotrexate ◽  
Refractory Rheumatoid Arthritis ◽  
Healthy Female

Low dose methotrexate has been used successfully to treat patients with refractory rheumatoid arthritis.1 Methotrexate-induced pneumonitis occurs in about 1 to 5% of patients, although opportunistic infections have also been reported.1 We report a case of fatal pneumocystis carinii pneumonia (PCP) in an otherwise healthy female patient treated with methotrexate for rheumatoid arthritis and review the literature.

scholarly journals Intermittent cyclophosphamide in refractory rheumatoid arthritis.

BMJ ◽  
1983 ◽  
Vol 287 (6394) ◽  
pp. 711-712 ◽  
Author(s):  
K Horslev-Petersen ◽  
J M Beyer ◽  
P Helin
Keyword(s):  
Rheumatoid Arthritis ◽  
Refractory Rheumatoid Arthritis
Sign in / Sign up

Export Citation Format

Share Document